Oncoloxía médica
Servicio
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (122)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583
-
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
Clinical and Translational Oncology
-
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8
-
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
Lung Cancer, Vol. 194
-
Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO)
Thrombosis Update, Vol. 17
-
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328
-
Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study
Clinical and Translational Oncology
-
Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology
Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 98-108
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663
-
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356
-
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 25, Núm. 11, pp. 1453-1464
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
-
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871
-
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Clinical and Translational Oncology
-
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789
2023
-
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925